See more : Boozt AB (publ) (0RPY.L) Income Statement Analysis – Financial Results
Complete financial analysis of China Resources Pharmaceutical Group Limited (3320.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China Resources Pharmaceutical Group Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- VersaCOM International, Inc. (VRCM) Income Statement Analysis – Financial Results
- The Sandesh Limited (SANDESH.BO) Income Statement Analysis – Financial Results
- Bulletin Resources Limited (BNR.AX) Income Statement Analysis – Financial Results
- Shanghai Dragon Corporation (600630.SS) Income Statement Analysis – Financial Results
- Revelation Biosciences, Inc. (REVBW) Income Statement Analysis – Financial Results
China Resources Pharmaceutical Group Limited (3320.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.crpharm.com
About China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.40B | 254.11B | 236.81B | 200.42B | 204.45B | 189.69B | 172.53B | 156.71B | 146.57B | 135.75B | 116.95B |
| Cost of Revenue | 227.03B | 214.97B | 201.43B | 168.13B | 170.44B | 154.76B | 144.26B | 132.60B | 123.37B | 114.26B | 96.80B |
| Gross Profit | 43.37B | 39.13B | 35.38B | 32.29B | 34.02B | 34.93B | 28.28B | 24.11B | 23.20B | 21.49B | 20.15B |
| Gross Profit Ratio | 16.04% | 15.40% | 14.94% | 16.11% | 16.64% | 18.41% | 16.39% | 15.39% | 15.83% | 15.83% | 17.23% |
| Research & Development | 2.61B | 2.09B | 1.69B | 1.32B | 1.15B | 1.04B | 908.18M | 789.42M | 781.14M | 944.79M | 730.62M |
| General & Administrative | 6.33B | 6.48B | 6.23B | 5.56B | 5.20B | 4.70B | 4.20B | 3.88B | 3.84B | 4.25B | 3.67B |
| Selling & Marketing | 18.91B | 19.03B | 17.53B | 16.03B | 19.19B | 18.34B | 13.87B | 10.95B | 10.11B | 8.80B | 8.42B |
| SG&A | 28.18B | 26.23B | 24.44B | 22.51B | 24.84B | 23.13B | 18.12B | 14.83B | 13.96B | 13.05B | 12.10B |
| Other Expenses | 0.00 | -1.73B | -1.40B | -558.49M | 706.10M | 467.25M | 451.40M | 311.62M | -211.80M | 43.57M | 304.30M |
| Operating Expenses | 29.35B | 28.32B | 26.13B | 23.82B | 25.99B | 23.27B | 17.88B | 14.31B | 13.29B | 13.05B | 12.10B |
| Cost & Expenses | 256.39B | 243.29B | 227.56B | 191.95B | 196.43B | 178.03B | 162.13B | 146.90B | 136.66B | 127.31B | 108.90B |
| Interest Income | 587.69M | 833.88M | 729.33M | 675.77M | 3.05B | 2.48B | 1.82B | 1.76B | 1.86B | 1.70B | 1.51B |
| Interest Expense | 2.39B | 2.86B | 2.71B | 3.16B | 3.72B | 2.94B | 2.27B | 1.83B | 2.09B | 2.13B | 1.77B |
| Depreciation & Amortization | 3.16B | 3.15B | 2.82B | 2.44B | 2.36B | 1.62B | 1.49B | 1.21B | 1.27B | 1.35B | 1.20B |
| EBITDA | 15.43B | 15.47B | 11.95B | 12.47B | 12.58B | 13.66B | 10.74B | 9.95B | 9.15B | 8.32B | 7.72B |
| EBITDA Ratio | 5.71% | 5.50% | 5.10% | 5.45% | 5.08% | 6.31% | 6.22% | 6.07% | 6.24% | 7.52% | 8.30% |
| Operating Income | 12.15B | 10.81B | 9.25B | 8.47B | 8.02B | 10.44B | 9.29B | 8.32B | 7.88B | 8.85B | 8.51B |
| Operating Income Ratio | 4.49% | 4.26% | 3.91% | 4.23% | 3.92% | 5.51% | 5.38% | 5.31% | 5.38% | 6.52% | 7.28% |
| Total Other Income/Expenses | -2.27B | -2.45B | -2.38B | -2.51B | -3.80B | -3.69B | -2.50B | -1.12B | -1.84B | -3.32B | -3.11B |
| Income Before Tax | 9.88B | 9.47B | 8.09B | 6.87B | 6.50B | 9.18B | 8.58B | 8.04B | 8.05B | 6.92B | 6.91B |
| Income Before Tax Ratio | 3.65% | 3.73% | 3.42% | 3.43% | 3.18% | 4.84% | 4.97% | 5.13% | 5.49% | 5.10% | 5.91% |
| Income Tax Expense | 2.11B | 2.01B | 1.76B | 1.75B | 1.54B | 1.61B | 1.72B | 2.07B | 1.97B | 1.43B | 1.46B |
| Net Income | 3.85B | 3.50B | 3.08B | 2.78B | 3.29B | 4.04B | 3.48B | 2.82B | 2.85B | 2.65B | 2.64B |
| Net Income Ratio | 1.43% | 1.38% | 1.30% | 1.39% | 1.61% | 2.13% | 2.02% | 1.80% | 1.94% | 1.95% | 2.26% |
| EPS | 0.68 | 0.66 | 0.60 | 0.52 | 0.52 | 0.64 | 0.55 | 0.57 | 0.62 | 0.43 | 0.43 |
| EPS Diluted | 0.68 | 0.66 | 0.60 | 0.52 | 0.52 | 0.64 | 0.55 | 0.57 | 0.62 | 0.43 | 0.43 |
| Weighted Avg Shares Out | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B | 4.91B | 4.63B | 6.17B | 6.17B |
| Weighted Avg Shares Out (Dil) | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B | 4.91B | 4.63B | 6.17B | 6.17B |
Source: https://incomestatements.info
Category: Stock Reports